PDCD1 and non-small cell lung carcinoma: In an effort to explore whether LDRT or HDRT, in combination with ICIs, could induce a systemic immune response, Schoenfeld et al69 conducted a phase-II clinical study involving patients with nonresponsive NSCLC to anti-PD-1 or anti-PD-L1 therapy.